Stem cell research is often controversial but it has also led to incredible medical progress in recent years.
Stem cell research is at defining moment. Although it can be controversial and does raise a lot of important ethical issues, this area of medical science has been characterised by a number of important advances, ever since the first embryonic stem cells were isolated from mice in the 1980s. In the near future, it could reshape the way we treat some of the world’s most debilitating diseases.
Stem cells have already been used as treatment for a number of years – think bone marrow transplant – and they have the potential to help with many other medical conditions. Continue Reading »
MOST doctors study for years so they can help others but for Southport’s Dinesh Palipana, it is much more personal.
A month out from his graduation ceremony at Griffith University, the 32-year-old doesn’t just want to help others, he also wants to help himself.
“I’ve had a vested interest and a passion to cure spinal cord injury and cure myself in the process,” he said.
Part-way through his medical degree in 2010, Mr Palipana was driving home to the Gold Coast from visiting his parents in Brisbane when his car aquaplaned on a wet road and overturned near the Gateway Bridge. Continue Reading »
Chronic pain and loss of bladder control are among the most devastating consequences of spinal cord injury, rated by many patients as a higher priority for treatment than paralysis or numbness. Now a UC San Francisco team has transplanted immature human neurons into mice with spinal cord injuries, and shown that the cells successfully wire up with the damaged spinal cord to improve bladder control and reduce pain. This is a key step towards developing cell therapies for spinal cord injury in humans, say the researchers, who are currently working to develop the technique for future clinical trials. Continue Reading »
Initial Results Offer Hope for Patients to Reclaim Independence After Suffering Severe Spinal Injury
LOS ANGELES, Sept. 7, 2016 /PRNewswire/ — Keck Medical Center of USC today announced that a team of doctors became the first in California to inject an experimental treatment made from stem cells, AST-OPC1, into the damaged cervical spine of a recently paralyzed 21-year-old man as part of a multi-center clinical trial. Continue Reading »
Oakland, CA – A clinical trial using stem cells to treat people with recent spinal cord injuries has cleared two key safety hurdles, and been given approval to expand the therapy to a larger group of patients with a much higher dose of cells.
Asterias Biotherapeutics announced that its Data Monitoring Committee (DMC) has reviewed the safety data from the first two groups of patients treated and found no problems or adverse side effects. One group of three patients was given 2 million cells. The second group of five patients received 10 million cells. Asterias is now cleared to enroll another 5-8 patients with 20 million cells. Continue Reading »
Background: Pre-clinical investigations in animal models demonstrate that enhanced upper-limb (UL) activity during rehabilitation promotes motor recovery following spinal cord injury (SCI). Despite this, following SCI in humans, no commonly applied training protocols exist and therefore activity-based rehabilitative therapies (ABRT) vary in frequency, duration and intensity. Quantification of UL recovery is limited to subjective questionnaires or scattered measures of muscle function and movement tasks. Continue Reading »
Our lab mission is to INSPIRE (integrate sensorimotor plasticity and interventions to promote recovery) persons with neurologic injury to regain function.
We are an interdisciplinary team of engineers, physiologists, neuroscientists, and clinicians that share a common mission: to study plasticity-inducing therapies directed at enhancing sensorimotor recovery in persons with catastrophic injury to their brain and/or spinal cord.
StemCells Inc., a California-based biotech company announced that they will stop developing the potential treatment for spinal cord injury after a failed mid-stage clinical trial. The company stock went down to $3.03 per share at the start of the pre-market trade. StemCells reported that they still have $5.5 million in cash as of May 31, but they don’t have a liquidating distribution to their stockholders.
The company said that the amount that they can give to the shareholders depends on the liquid assets, any liabilities, and costs of the wind down. Continue Reading »
Company will Collaborate with The University of Pittsburgh to Develop an Implantable Device for Spinal Cord Injury Patients
SAN ANTONIO, May 24, 2016 /PRNewswire/ — InCube Labs, a multi-disciplinary life sciences R&D lab, today announced that it has been awarded a subcontract from the University of Pittsburgh to help develop an implantable neuromodulation therapy to restore bladder function for spinal cord injury (SCI) patients. Continue Reading »